CGTLive®’s Weekly Rewind – June 14, 2024

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Pfizer’s Phase 3 Trial for DMD Gene Therapy Fordadistrogene Movaparvovec Misses the Mark on Primary End Point

Pfizer additionally noted that the trial missed the mark on key secondary end points.

2. Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma

The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.

3. NKGen Continues Progress Evaluating SNK01 NK Cell Therapy for Alzheimer Disease

The phase 1/2 trial is proceeding to its phase 2 trial after safety was demonstrated in its first phase.

4. Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease

The director of the Mount Sinai Fuster Heart Hospital discussed how artificial intelligence complements data-driven research.

5. Myasthenia Gravis Awareness Month 2024: Looking Back at a Year of Progress for CAR-T

In observance of Myasthenia Gravis Awareness Month, held annually in June, we took a look back at a year of progress in bringing CAR-T to this autoimmune disease.